ReviewGenes & diseases2025
The role of SOX transcription factors in prostate cancer: Focusing on SOX2.
Review in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A fatty acid metabolism-based deep learning model predicts biochemical recurrence and identifies NUDT19 as a candidate metabolic factor in prostate cancer.World journal of surgical oncology · 2026Article
- ZBTB7A promotes malignant phenotypes in ovarian cancer through transcriptional activation of CRLF1.Oncology reports · 2026Article
- From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer remains a major health problem, with its incidence ranking second among male malignancies worldwide. Recent studies have highlighted the critical role of the SOX family transcription factors, especially SOX2, in prostate cancer pathogenesis. SOX2 regulates the fate of cancer stem/progenitor cells, contributing to tumor initiation, development, and metastasis. Elevated SOX2 levels have been detected in prostate cancer tissues and are associated with higher tumor grade, aggressive phenotype, and poor prognosis. SOX2 also impacts various tumor biological behaviors, including cell proliferation, invasion, metastasis, resistance to apoptosis, and treatment resistance. This review highlights the role of SOX proteins in prostate cancer, focusing on the molecular mechanisms by which SOX2 drives cancer progression, elucidating the mechanisms controlling its activity, and emphasizing its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.